RegulatoryCompany release

Vir Biotechnology's VIR-5500 gets FDA Fast Track as hepatitis delta Phase 3 readout nears

🇺🇸 Vir Biotechnology, Inc. (VIR) · Wed 04 Nov 2026

Vir's Q3 update reports Fast Track for its PSMA-targeted T-cell engager in prostate cancer, a Gilead deal worth $90 million upfront, and an imminent hepatitis delta Phase 3 readout.

Vir Biotechnology said on 4 November 2026, alongside its third-quarter results, that the US Food and Drug Administration has granted Fast Track designation to VIR-5500. The candidate is a PSMA-targeted T-cell engager being developed for late-line metastatic castration-resistant prostate cancer.

The company plans to begin pivotal trials of VIR-5500 in 2027. Fast Track is an FDA programme intended to speed the development and review of drugs for serious conditions with unmet need, and it allows more frequent interaction with the agency. It does not guarantee approval.

Vir also said topline results from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026. The study tests elebsiran in combination with tobevibart in chronic hepatitis delta.

On the corporate side, Vir has signed a collaboration with Gilead that includes $90 million upfront. The company reported roughly $901 million in cash at the end of the quarter. The summary available does not give further terms of the Gilead agreement.

What it means for your team

  • Regulatory teams tracking oncology should note that VIR-5500 now has Fast Track status, with pivotal trials slated for 2027.
  • The ECLIPSE 1 topline readout, due in Q4 2026, is the next key event for the hepatitis delta field and could shape future filing plans.
  • Market-access teams may want to follow the Gilead collaboration, although its wider terms were not detailed in the information available.

Company's press release (SEC filing): Vir Biotechnology, Inc. ↗

Article written by VigiEye from the official source (Vir Biotechnology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →